Published Date: 22 Nov 2024
News and commentary from the world of neurology and neuroscience
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Surviving cancer, still suffering: Survey reveals gaps in follow‑up care
4.
Charles III, King of Kings, is Cancerous.
5.
The Truth About Apple AirPods
1.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
2.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
3.
Unveiling the Hidden Mechanisms of Hemolytic Reactions
4.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Q&A Session to Close the Gap
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation